Crossbow Therapeutics, Inc

We're #hiring! Come join my team at Crossbow Therapeutics, Inc! This is an exciting role spanning #ProgramManagement, #RnDOperations, #CorporateOperations, competitive intelligence and more! We're a dynamic, collaborative and innovative #biotech team that is boldly pushing to bring new #medicines to patients. If this sounds like a match, don't hesitate to #apply!

We are #hiring at Crossbow Therapeutics, Inc! Our Co-founder, VP of Corporate Development and Operations, Geraldine Paulus, is looking to bring on board an exciting new role as a senior manager or associate director, corporate operations and program management. Find out more about the position and how to apply in the Job Posting below.

We are delighted to announce that Dr. Charles Baum, MD, PhD has joined Crossbow Therapeutics, Inc's #board as an independent director. Chuck is an accomplished #biopharma exec who brings over 30 years of experience in #oncology and we look forward to benefitting from his deep expertise. You can find his full bio on our website's team section: https://lnkd.in/euQ2u9Fp

We are #hiring at Crossbow Therapeutics, Inc! Our antibody discovery, protein engineering and process development team is looking to bring on board a Sr. RA or Associate Scientist in Protein Analytics. Find out more about the position and how to apply in the Job Posting below. #cancer #immunooncology #antibody #protein #analytics

We are #hiring at Crossbow Therapeutics, Inc! Our head of Translational Medicine, Benjamin Lee is looking to bring on board an associate director to his team. Find out more about the position and how to apply in the Job Posting below. #cancer #translational medicine #immunooncology

We're excited to be featured by BioCentury Inc. in one of the Emerging Company Profiles. Briggs Morrison, Dmitri Wiederschain and Geraldine Paulus enjoyed speaking with Karen Tkach Tuzman to discuss Crossbow Therapeutics, Inc's approach to open up the target space in oncology as well as its first drug candidate CBX-250. Read the full article here: https://lnkd.in/eEpPAvxV

Last week, our head of Translational Medicine, Benjamin Lee, gave a talk at the 6th Annual Cell Engager Summit (https://lnkd.in/eSZynx9) in Boston. Another great opportunity to highlight Crossbow Therapeutics, Inc's lead program, CBX-250, a novel T cell engager targeting a peptide-HLA complex for the treatment of #AML and other heme malignancies!

Today, Crossbow Therapeutics, Inc is presenting data on our first TCR-mimetic T Cell Engager at the 5th TCR-based Therapies for Solid Tumors Summit. Check out our talk and the program in the full event guide here: https://ter.li/atzlcp.

Great shots by our CSO Dmitri Wiederschain who captured our co-founder Geraldine Paulus on stage at #AACR2024 presenting data on Crossbow Therapeutics, Inc first DC, CBX-250 . Bonus points if you spot our other co-founder and SAB member Patrick A. Baeuerle in the front row!

If you are attending #AACR2024, we invite you to come to our oral presentation, where we'll discuss the characterization of Crossbow Therapeutics, Inc's first development candidate, CBX-250, a TCR-mimetic-based T Cell Engager targeting a Cathepsin G peptide-HLA complex. Details below.